Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b

Noriko Sasase, Soo Ryang Kim, Masatoshi Kudo, Ke Ih Kim, Miyuki Taniguchi, Susumu Imoto, Keiji Mita, Yoshitake Hayashi, Ikuo Shoji, Ahmed El-Shamy, Hak Hotta

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

We investigated whether sustained virological response (SVR) and non-SVR by chronic hepatitis C patients to pegylated interferon plus ribavirin (PEG-IFN/RBV) combination therapy are distinguishable by viral factors such as the IFN/RBV resistance-determining region (IRRDR) and by on-treatment factors through new indices such as the rebound index (RI). The first RI (RI-1st; the viral load at week 1 divided by the viral load at 24 h) and the second RI (RI-2nd; the viral load at week 2 divided by the viral load at 24 h) were calculated. The subject patients were divided into 3 groups based on RI-1st and RI-2nd: an RI-A group (RI-1st ≤1.0), an RI-B group (RI-1st >1.0 and RI-2nd <0.7) and an RI-C group (RI-1st >1.0 and RI-2nd ≥0.7). The SVR rate was 71.4% (10/14) in the RI-A group, 46.2% (6/13) in the RI-B group and 20.0% (3/15) in the RI-C group (p = 0.005 between the RI-A group and the RI-C group). In IRRDR ≥6 and IRRDR ≤5 the SVR rate was 81.3% (13/16) and 23.1% (6/26) (p = 0.0002), respectively. By combining RI and IRRDR as a predicting factor, the SVR rate was 87.5% (7/8) in the RI-A group (≥6 mutations in the IRRDR) and 7.7% (1/13) in the RI-C group (≤5 IRRDR mutations) (p = 0.0003).

Original languageEnglish
Pages (from-to)49-54
Number of pages6
JournalIntervirology
Volume53
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Keywords

  • Chronic hepatitis
  • Early viral dynamics
  • HCV RNA genotype 1b
  • High viral load
  • IFN/RBV resistance-determining region
  • PEG-IFN/RBV combination therapy
  • Virological response, prediction

Fingerprint

Dive into the research topics of 'Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b'. Together they form a unique fingerprint.

Cite this